Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

類似資料

• Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors
  著者:: Hamamoto, Junko, 等
  出版事項: (2017)
• Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
  著者:: NUKAGA, SHIGENARI, 等
  出版事項: (2016)
• Secondary Brain Neoplasm after Stereotactic Radiosurgery in Patients with Metastatic Non-small Cell Lung Cancer
  著者:: Nukaga, Shigenari, 等
  出版事項: (2018)
• In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
  著者:: Hirano, Toshiyuki, 等
  出版事項: (2015)
• EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib
  著者:: Kobayashi, Keigo, 等
  出版事項: (2017)